[music] Hello and welcome to Asking for a Trend. I'm Josh Lipton and for the next half hour, we are breaking down the trends of today that are move stocks tomorrow. There's a lot to keep track of, so we're focusing on what [music] you need to know to get ahead of the curve.Here are some of the trends we're going to be diving right into. The cannabis industry has high hopes for President Trump. The White House may finally be rescheduling [music] marijuana's drug classification.We're going to hear from the CE ...

Core Insights - JAZZ Pharmaceuticals is an unconventional player in the cannabis sector, having entered the market through the acquisition of GW Pharmaceuticals in 2021, which added the FDA-approved CBD drug Epidiolex to its portfolio [1][2] - The company is well-positioned for long-term gains as the medical cannabis market evolves and regulatory clarity improves [2] Epidiolex's Contribution - Epidiolex has become a significant revenue contributor, accounting for a quarter of JAZZ's total revenues [3] - In the first nine months of 2025, Epidiolex generated over $772 million in product sales, reflecting an 11% year-over-year increase [4] - The global medical cannabis market is projected to exceed $130 billion by 2032, providing JAZZ with a unique opportunity due to its established FDA-approved product [5] Diverse Product Lineup - JAZZ has a diverse product lineup beyond cannabis, including drugs for neuroscience and oncology [6] - Xywav, a low-sodium formulation for narcolepsy, is a key product that offers advantages over its predecessor, Xyrem [7] - The oncology segment includes six drugs that now contribute over 26% to JAZZ's topline, driven by new launches and increased market share [8] Pipeline Developments - JAZZ is focused on expanding the labels of its oncology drugs, with promising results for Ziihera in treating HER2+ gastroesophageal adenocarcinoma [9] - Despite setbacks in its pipeline, including the discontinuation of suvecaltamide and underwhelming results for JPZ150, the company continues to explore options for its drug development [12][13] Stock Performance and Outlook - JAZZ's stock has surged 46% year-to-date, outperforming the industry average of 20% [14] - EPS estimates for 2025 and 2026 have trended upward, indicating a stronger outlook compared to other cannabis-focused companies [15] - The company offers a diversified revenue base, making it suitable for investors seeking balanced biotech exposure rather than a direct cannabis investment [16][17]

Core Insights - IM Cannabis Corp. is set to report its operational and financial results for Q3 2025 on November 13, 2025, before market opening [1] Company Overview - IM Cannabis Corp. is an international cannabis company focused on providing premium cannabis products to medical patients in Israel and Germany, which are among the largest medical cannabis markets [2] - The company aims for sustainable and profitable growth in its key markets, leveraging a data-driven approach and a globally sourced product supply chain [2] - IM Cannabis is committed to responsible growth and compliance with strict regulatory environments to enhance its commercial and brand power [2] Operational Ecosystem - The IMC ecosystem operates in Israel through subsidiaries that import and distribute cannabis to medical patients, utilizing proprietary data and patient insights [3] - The company manages medical cannabis retail pharmacies, online platforms, distribution centers, and logistical hubs in Israel to ensure safe delivery and quality control of its products [3] - In Germany, IM Cannabis operates through Adjupharm GmbH, distributing cannabis to pharmacies for medical cannabis patients [3]

Core Viewpoint - Cannabis stocks experienced significant gains following President Donald Trump's promotion of a video advocating for the inclusion of cannabidiol (CBD) under Medicare coverage [1][6]. Group 1: Stock Performance - Tilray Brands surged nearly 20% and was up 36% after market open [1]. - Canopy Growth jumped about 20%, while Cronos Group rose 13% [1]. - Aurora Cannabis climbed 13.3%, and Trulieve Cannabis spiked almost 20% [1]. - Green Thumb Industries, Curaleaf Holdings, and Innovative Industrial Properties also saw considerable share price increases [3]. Group 2: Video Promotion and Content - The video produced by The Commonwealth Project features Trump and a narrator advocating for wider access to CBD for seniors [6][9]. - The narrator claims that hemp-derived CBD can significantly improve the quality of life for older adults [7][10]. - The video suggests that CBD can help restore the endocannabinoid system and assist with pain, sleep, and stress [10]. Group 3: Regulatory Context - Trump previously indicated he was considering reclassifying marijuana as a less dangerous substance, although no action has been taken yet [8]. - The timing of the video promotion coincides with Congress deliberating on tightening hemp regulations, with some Republicans advocating for stricter limits on CBD products containing trace amounts of THC [8].

Financial Performance - High Tide Inc. reported record-high revenues, gross profit, and free cash flow for Q2-2025, marking it as the best quarter in the company's history [1] Market Expansion - High Tide has officially entered the German medical cannabis market, indicating a strategic expansion into new territories [1]

Core Insights - Aurora Cannabis Inc. is recognized as one of the 12 best marijuana stocks to buy according to analysts [1] - The company, in collaboration with Copeia, has launched an English-language version of the Physician Experience Platform (PEP), which includes over 130 anonymized case studies on medicinal cannabis treatments [1][2] - PEP aims to provide healthcare professionals with access to peer-reviewed clinical insights and is initially available in several countries including Canada, the UK, and Australia [1][2] Company Developments - The PEP platform builds on a successful German launch in 2024 and is secured by a DocCheck login for verified physicians [2] - Aurora Cannabis operates in the global medicinal and consumer cannabis markets under various brands such as MedReleaf, CanniMed, Drift, and San Rafael '71 [2] - The company intends to create an international medical cannabis case study database for physicians to upload cases in the future [2]

Core Insights - Tilray Medical is expanding its presence in Germany's medical cannabis market by introducing three new EU-GMP certified cannabis strains, enhancing patient and pharmacy access [1][2][3] Product Offerings - The new strains include Good Supply Cannabisblüten THC 22 IIM, THC 25 MMK, and THC 18 LLD, available in 15 g and 500 g sizes to cater to diverse needs [1][2] - Good Supply Cannabisblüten THC 22 IIM will be available from early September, THC 25 MMK from September 19, and THC 18 LLD by late September or early October [2] Market Positioning - Tilray Medical aims to be a trusted partner in medical cannabis, leveraging its robust international platform and distribution network to ensure consistent quality and reliable supply [2][3] - The company has established itself as a leading supplier of medical cannabis, with a portfolio that includes several recognized brands tailored for the German market [3][4] Company Background - Tilray Medical has evolved from being one of the first licensed producers of medical cannabis in Canada to building GMP-certified production facilities in Portugal and Germany [4] - The company is committed to providing safe and reliable access to a global portfolio of medical cannabis brands, including Good Supply, Broken Coast, Redecan, and Navcora [4] Strategic Goals - The introduction of new strains is part of Tilray's broader strategy to enhance healthcare standards and patient care globally [2] - The company emphasizes its dedication to transforming healthcare through informed health decisions and individualized patient care [1][2]

Regulatory Landscape & Policy Changes - The cannabis industry has been actively lobbying Washington, potentially leading to more favorable policies [2] - The Trump administration expressed support for cannabis and reducing uncertainty in the sector [2] - Rescheduling cannabis from Schedule I to Schedule III would significantly alter the industry's tax structure [2][4] - The FDA has acknowledged the medicinal use of cannabis in a 28-page memo [3] Market Dynamics & Investment Opportunities - State-by-state, cannabis legalization is consistently progressing, with adult, medical, and recreational markets being approved [6] - The cannabis market is estimated to be an $80 billion market, including adult, medical, and illicit sales [8] - Top-line growth is evident, attracting consumers seeking exposure to this growth [8] - Investing in the cannabis sector now allows investors to be ahead of institutional capital [8] Challenges & Considerations - Confusion exists regarding the business outlook due to complex legal and regulatory frameworks at both state and federal levels [5] - Restrictions on sales types vary across states where cannabis products are available [5] - Hemp-derived THC legalization through the farm bill adds complexity for investors [7] - Investing in the sector can be complicated, requiring a deep understanding of the industry [8]

Financial Data and Key Metrics Changes - The company reported consolidated net revenue of $33.5 million, a 21% increase year over year, with net revenue excluding Groco at $31.2 million, representing a 13% growth year over year [15][16] - Gross profit for Q2 was $14.5 million, equating to a 43% gross margin, significantly improved from 23% in Q2 2024 [16] - Adjusted EBITDA was $1.7 million, an improvement of $12.7 million year over year, driven by revenue growth and margin enhancement [17] Business Line Data and Key Metrics Changes - The Spinach brand ranked as the number two cannabis brand in Canada with a 4.7% market share across formats and number three in the flower category with a 4.9% market share [6] - In the vape category, Spinach achieved the number four position overall with a 6.5% market share and number two in the vape cartridge category with an 8.4% share [7] - The Lord Jones brand maintained a 28.5% market share in the hash-infused pre-roll segment, remaining the category leader [10] Market Data and Key Metrics Changes - Cronos Israel posted a record quarter with a 36% year-over-year revenue growth, becoming the number one flower brand in Israel with over 20% market share [10][12] - The company expanded its international presence, with Peace Naturals now available in seven key global markets, including Canada, Israel, Germany, the UK, Australia, Switzerland, and Malta [13] Company Strategy and Development Direction - The company aims to expand cultivation capacity at Groco and improve market share in Canada while focusing on higher-margin international markets [6] - Continued investment in innovative product launches, particularly in the vape and edibles categories, is a key strategic focus [9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the core business's strength and resilience, highlighting robust demand across key markets and product categories [5][21] - The company anticipates that the expansion at Groco will alleviate supply constraints and drive further growth [19] Other Important Information - The company maintains a strong balance sheet with no debt and cash equivalents and short-term investments totaling $834 million [13] - An investment of $18.5 million in High Tide through a convertible loan was made, with potential for equity conversion [19] Q&A Session Summary Question: No questions were raised during the session - The call concluded without any questions from participants [22]

Core Insights - Tilray Medical has launched its cannabis brand Good Supply in Germany, aiming to provide affordable and reliable medical cannabis options for patients [1][2][3] - The introduction of Good Supply reflects Tilray's commitment to enhancing patient care and empowering healthcare professionals with innovative medical cannabis solutions [2][3] - Good Supply offers a variety of cannabis strains, available in both 15g and 500g, catering to the diverse needs of patients [2][7] Company Overview - Tilray Medical is a leading player in the global medical cannabis industry, with operations in Canada, Portugal, and Germany, and is recognized for its commitment to quality and innovation [3][4] - The company has established itself as a trusted supplier of medical cannabis, with a portfolio that includes multiple brands designed to meet patient needs worldwide [4][6] - Tilray Brands, Inc. operates as a global lifestyle and consumer packaged goods company, focusing on cannabis, wellness, and entertainment, with a mission to inspire joy and create memorable experiences [6]